at ENF use, ENF use in the failures was comparable between arms at 45%.
|About 70% of
subjects developed ENF resistance mutations on treatment in the MVC QD and
|And There were
significantly fewer ENF resistance mutations that developed in the MVC BID
arm than in the placebo arm (p=0.01) or the MVC QD arm (p =0.02).